Basic Information
LncRNA/CircRNA Name | UCA1 |
Synonyms | UCA1, CUDR, LINC00178, NCRNA00178, UCAT1, onco-lncRNA-36 |
Region | GRCh38_19:15828206-15836326 |
Ensemble | ENSG00000214049 |
Refseq | NR_015379 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | Cisplatin | ||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | lung adenocarcinoma |
ICD-0-3 | C34 |
Methods | Microarray, qPCR |
Sample | cell lines (A549, NCI-H1299, A549/DDP) |
Expression Pattern | differential expression |
Function Description | We found that 1,543 lncRNAs and 1,713 mRNAs were differentially expressed in A549/DDP cell and A549 cell, hinting that many lncRNAs were irregular from cisplatin resistance in LAD. UCA1 was the aberrantly expressed lncRNA and can significantly reduce the IC50 of cisplatin in A549/DDP cell after knockdown, while it can increase the IC50 of cisplatin after UCA1 was overexpressed in NCI-H1299. |
Pubmed ID | 29279851 |
Year | 2017 |
Title | Aberrant Long Noncoding RNAs Expression Profiles Affect Cisplatin Resistance in Lung Adenocarcinoma |
External Links
Links for UCA1 | GenBank HGNC NONCODE |
Links for lung adenocarcinoma | OMIM COSMIC |